Company intelligence / Profile preview

Ocuspecto

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

The company’s main product, the Ocusweep device, has been used in at least two clinical trials to assess neurovisual function in patients with glaucoma and/or mild cognitive impairment. The studies aim to correlate performance on the Ocusweep with traditional measures of fitness to drive. No published pivotal or regulatory trial results are available as of March 2025.

Therapeutic areas: OphthalmologyNeurology
Modalities: Device (specifically neurovisual function assessment device)
Industry: Physiological Monitoring

Partnerships

Academic medical centers conducting clinical research using the device; specific institutions not listed publicly.

Beyond the preview

Go deeper on Ocuspecto.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocuspecto.

Explore the full profile